Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 20, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Market Cap	248	771	482	538	804	1,363
Market Cap Growth	-67.23%	60.15%	-10.40%	-33.17%	-40.97%	382.72%
Enterprise Value	115.68	668.77	349.45	386.51	655.21	1,211
Last Close Price	2.68	8.90	5.68	6.55	10.32	17.95
PB Ratio	1.95	8.13	4.00	3.79	5.65	9.04
P/TBV Ratio	1.83	8.00	3.94	3.68	5.57	8.31
Net Debt / Equity Ratio	-1.04	-1.08	-1.10	-1.06	-1.05	-1.01
Net Debt / EBITDA Ratio	2.95	2.00	2.50	2.71	2.93	3.62
Net Debt / FCF Ratio	3.87	2.63	4.29	5.44	6.15	5.01
Quick Ratio	20.81	11.56	8.80	12.27	14.92	14.93
Current Ratio	20.87	11.60	8.86	12.32	14.95	14.97
Return on Equity (ROE)	-4.78%	-43.11%	-32.81%	-33.41%	-32.47%	-42.28%
Return on Assets (ROA)	-34.92%	-42.95%	-36.47%	-36.32%	-32.44%	-42.82%
Return on Invested Capital (ROIC)	672.03%	571.68%	546.90%	770.31%	1442.56%	2938.99%
Return on Capital Employed (ROCE)	-37.55%	-47.79%	-40.35%	-39.22%	-34.77%	-47.18%
Buyback Yield / Dilution	-2.61%	-2.18%	-4.61%	-3.74%	-10.18%	-19.95%
Total Shareholder Return	-2.61%	-2.18%	-4.61%	-3.74%	-10.18%	-19.95%

Updated Feb 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q